Therapeutic Area
Structural Heart Disease Clinical Trials — Amavita Research
Cardiovascular trial site for structural heart disease, conducted at amavita Heart and Vascular Health® in North Miami Beach, FL.
Structural heart disease — including aortic stenosis, mitral regurgitation, and tricuspid regurgitation — is one of the most active device-trial spaces in cardiovascular medicine, covering TAVR, transcatheter mitral and tricuspid repair, and circulatory support. Trial conduct in this area requires deep procedural and consultative experience. Here is the subspecialty depth Amavita Research brings.
Active trials at Amavita Research
No active trials in this indication at this time. Sponsors evaluating Amavita Research for a structural heart disease protocol can reach out via /contact-sponsor.
Principal Investigators in this area
Why Amavita Research for structural heart disease trials
- Dr. William W. O'Neill, MD, FACC — National PI on the Edwards PARTNER, Protect II, and Protect IV trials; pioneer of TAVR in the United States.
- TAVR / Impella legacy with high-acuity case experience, including cardiogenic shock protocols (National Cardiogenic Shock Initiative).
- Direct cath-lab and structural-heart consultation via amavita Heart and Vascular Health® and the affiliated Advanced Cardiovascular of Miami ambulatory surgical center.
- Coordination capability with major academic structural-heart programs (e.g., Henry Ford Hospital Center for Structural Heart Disease).
- Cross-border trial designs supported via bioaccess® — sponsors can integrate Amavita Research as the U.S. arm and bioaccess® as the Latin America first-in-human arm under a single coordinated design.
Think you might be eligible for a structural heart disease trial?
Call (786) 703-5941 or use the patient contact form — initial screening is free and takes about 15 minutes.